How Paragraph IV Patent Challenges Speed Up Generic Drug Entry
Paragraph IV certification under the Hatch-Waxman Act allows generic drug makers to challenge brand-name patents before they expire, speeding up affordable drug access. Here's how it works, why it matters, and who wins.
Read More
